Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

While targeted therapy against HER2 is an effective first-line treatment in HER2(+) breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here, we show that lapatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Claus, Jeroen, Patel, Gargi, Autore, Flavia, Colomba, Audrey, Weitsman, Gregory, Soliman, Tanya N, Roberts, Selene, Zanetti-Domingues, Laura C, Hirsch, Michael, Collu, Francesca, George, Roger, Ortiz-Zapater, Elena, Barber, Paul R, Vojnovic, Boris, Yarden, Yosef, Martin-Fernandez, Marisa L, Cameron, Angus, Fraternali, Franca, Ng, Tony, Parker, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929906/
https://www.ncbi.nlm.nih.gov/pubmed/29712619
http://dx.doi.org/10.7554/eLife.32271

Ejemplares similares

Ejemplares similares